Skip to main content

Table 1 The clinical characteristics of the patients from whom the high grade serous ovarian carcinoma samples were obtained

From: Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer

Patient

Age at diagnosis (Years)

Stage

Grade

Progression free survival (Months)

Overall survival (Months)

Current status

OV1

59

IV

3

22.8

74.4

Deceased

OV2

64.5

IIIC

3

N/A

N/A

N/A

OV3

38.3

IV

3

34.1

86.4

Alive

  1. All patients underwent primary debulking surgery for advanced stage ovarian cancer and had optimal cytoreduction. One patient was lost to follow up and therefore recurrence and overall survival data are not available
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us